Hims & Hers Health's Q3 Earnings Call: Our Top 5 Analyst Questions [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
by surging demand for personalized care, new specialty launches, and expanding international reach. Management credited its vertically integrated compounding infrastructure and the transition to multi-condition daily treatments for fueling scale and efficiency. CEO Andrew Dudum highlighted that “subscribers using personalized solutions grew 50% year-over-year,” underscoring the company's evolution from serving narrow health needs to supporting a broad array of conditions. The company's ability to leverage its growing customer base for improved engagement and operational learnings featured prominently in its assessment of the quarter. Is now the time to buy HIMS? Find out in our full research report (it's free for active Edge members). Hims & Hers Health (HIMS) Q3 CY2025 Highlights: Revenue: $599 million vs analyst estimates of $579.6 million (49.2% year-on-year growth, 3.3% beat) Adjusted EPS: $0.28 vs analyst estimates of $0.23 (20.4% beat) Adjusted EBITDA: $78.37 million v
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (NYSE:HIMS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Hims & Hers Continues Major International Expansion With Official Entry Into Canada [Yahoo! Finance]Yahoo! Finance
- A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity [Seeking Alpha]Seeking Alpha
- Humana And Mark Cuban's Cost Plus Drugs Working On Partnership To Lower Prices [Forbes]Forbes
- Hims & Hers Health, Inc. (HIMS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 11/25/25 - Form 4
- HIMS's page on the SEC website